Peptide vaccination against multiple myeloma using peptides derived from anti-apoptotic proteins: a phase I trial

TY - JOUR

T1 - Peptide vaccination against multiple myeloma using peptides derived from anti-apoptotic proteins

T2 - a phase I trial

AU - Jørgensen, Nicolai Grønne

AU - Ahmad, Shamaila Munir

AU - Abildgaard, Niels

AU - Straten, Per Thor

AU - Svane, Inge Marie

AU - Andersen, Mads Hald

AU - Knudsen, Lene Meldgaard

PY - 2016

Y1 - 2016

N2 - The B-cell lymphoma-2 (Bcl-2) family of proteins play a crucial role in multiple myeloma (MM), contributing to lacking apoptosis which is a hallmark of the disease. This makes the Bcl-2 proteins interesting targets for therapeutic peptide vaccination. We report a phase I trial of therapeutic vaccination with peptides from the proteins Bcl-2, Bcl-XL and Mcl-1 in patients with relapsed MM. Vaccines were given concomitant with bortezomib. Out of 7 enrolled patients, 4 received the full course of 8 vaccinations. The remaining 3 patients received fewer vaccinations due to progression, clinical decision of lacking effect and development of hypercalcemia, respectively. There were no signs of toxicity other than what was to be expected from bortezomib. Immune responses to the peptides were seen in all 6 patients receiving more than 2 vaccinations. Three patients had increased immune responses after vaccination. Vaccination against Bcl-2 was well tolerated and was able to induce immune responses in patients with relapsed MM.

AB - The B-cell lymphoma-2 (Bcl-2) family of proteins play a crucial role in multiple myeloma (MM), contributing to lacking apoptosis which is a hallmark of the disease. This makes the Bcl-2 proteins interesting targets for therapeutic peptide vaccination. We report a phase I trial of therapeutic vaccination with peptides from the proteins Bcl-2, Bcl-XL and Mcl-1 in patients with relapsed MM. Vaccines were given concomitant with bortezomib. Out of 7 enrolled patients, 4 received the full course of 8 vaccinations. The remaining 3 patients received fewer vaccinations due to progression, clinical decision of lacking effect and development of hypercalcemia, respectively. There were no signs of toxicity other than what was to be expected from bortezomib. Immune responses to the peptides were seen in all 6 patients receiving more than 2 vaccinations. Three patients had increased immune responses after vaccination. Vaccination against Bcl-2 was well tolerated and was able to induce immune responses in patients with relapsed MM.

KW - Journal Article

U2 - 10.21037/sci.2016.11.09

DO - 10.21037/sci.2016.11.09

M3 - Journal article

C2 - 28078275

SN - 2306-9759

VL - 3

JO - Stem Cell Investigation

JF - Stem Cell Investigation

M1 - 95

ER -